Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if Lapatinib has any effect on tumors found in
patients with Neurofibromatosis Type 2 (NF2). NF2 is a condition that mainly affects the skin
and nervous system. It causes non-cancerous tumors (which are known as neuromas) to grow on
the nerves around a person's body. Some signs of NF2 include a gradual loss of hearing and
tumors growing on the skin, the brain and the spinal cord which can lead to complications.
Lapatinib is an oral drug that is approved by Food and Drug Administration (FDA) for other
types of tumors, it is not approved by the FDA for treatment of NF2 related tumors. The
investigators know a lot about how well it is tolerated, but the investigators do not know if
it is effective in treating your condition, therefore it is considered to be an
investigational medication. This study will test whether Lapatinib may shrink tumors commonly
found in patients with NF2 or stop them from growing. This will help us to decide if
Lapatinib should be used to treat NF2 patients in future. Lapatinib is a drug that has been
used for over 10 years to treat various forms of cancer. It has not been studied for the
treatment of tumors in NF2 patients.
Phase:
Phase 2
Details
Lead Sponsor:
New York University School of Medicine NYU Langone Health